Here’s a roundup of companies announcing new distribution deals.
- Glenveigh lands distribution deal for Monica Healthcare’s wireless fetal monitor
Glenveigh Medical LLC and Monica Healthcare Ltd. signed an agreement for exclusive distribution rights in the United States as well as U.S. territories and military bases for Monica Healthcare’s AN24 wireless fetal monitoring system. The system recently received Food & Drug Administration 510(k) clearance for use during labor and delivery. Marketed under the trade name Beacon by Monica, the wireless fetal monitoring system will be available in U.S. hospitals exclusively through Glenveigh and promoted by Glenveigh’s sales and distribution partner Norgenix Pharmaceuticals LLC. Glenveigh is a life science and technology company focused on advancing the practice of obstetrics worldwide. United Kingdom-based Monica Healthcare develops wireless technologies for use in obstetrics.
- Health Robotics cancels McKesson deal
Health Robotics gave notice to McKesson Corp. (NYSE:MCK) for the immediate termination of the companies’ exclusive CytoCare distribution and services contract in North America, as well as the termination of their non-exclusive distribution agreement for i.v.STATION and i.v.SOFT within a subset of McKesson Automation’s customers. Health Robotics does not expect this early termination to have a material impact on its overall North American installations given the fact that McKesson’s contracts represented less than 10 percent of all Health Robotics’ contracted installations in the U.S. and Canada since the companies executed their initial IV Automation agreement in August 2009. More specifically, i.v.STATION and i.v.SOFT customers should not be disrupted at all by this termination due to the fact that 100 percent of these installations were contracted for and implemented by non-McKesson Health Robotics’ partners and their associates, who will continue to support these i.v.STATION and i.v.SOFT customers without pause. Until further notice and pending regulatory compliance review, CytoCare customers that have contracts with McKesson Automation should refer their questions about ongoing maintenance and support to McKesson.
- Epigenomics and Qiagen sign colorectal cancer biomarker deal
Epigenomics AG (FWB:ECX), the cancer molecular diagnostics company, and QIAGEN N.V. (NSDQ:QGEN) entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics’ proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies. Under the terms of the agreement, QIAGEN receives an option to a worldwide non-exclusive commercial license to Epigenomics’ proprietary mSEPT9 biomarker and DNA methylation technologies for the detection of colorectal cancer in blood. The option can be exercised by QIAGEN within the next two years. Furthermore, Epigenomics has granted QIAGEN a research license to the mSEPT9 biomarker and the technologies. Under this license, QIAGEN is currently developing a novel sample preparation technology that meets the requirements for the future broad implementation of methylation-based molecular diagnostics, such as Septin9-targeted blood testing for the detection of colorectal cancer, on QIAGEN’s modular molecular testing platform QIAsymphony. Epigenomics will support QIAGEN in the R&D phase through know-how transfer and the collection of clinical specimens as required.
- Fluidigm signs Eisenberg Brothers Ltd. for Israel distribution deal
Fluidigm Corp. (NSDQ:FLDM), the inventor of integrated fluidic circuits (IFCs), appointed Eisenberg Brothers Ltd. as its distributor in Israel. Eisenberg Brothers will offer Fluidigm’s complete portfolio of BioMark, EP1, and Access Array Systems and the complete line up of Dynamic Array, Digital Array and Access Array IFCs for real-time PCR, digital PCR, genotyping, gene expression, copy number variation and absolute quantification for sequencing. Eisenberg Brothers has a 50-year history in providing high end genetic analysis solutions to research organizations and businesses.
- Quanterix Announces New Technology Evaluation Agreemen
Cambridge, Mass.-based Quanterix Corp. entered into an evaluation agreement with Novartis Diagnostics for the purpose of ascertaining the potential use of Quanterix’s SiMoA platform technology for diagnostic use. The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target. Quanterix is developing its proprietary Single Molecule Array (SiMoA) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA has the potential to yield unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity when compared with analog-only technology.